Extended Data Fig. 7: Reduced eosinophils in Ret tumor-bearing ILC2 deficient mice.
From: Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
Myeloid immune cell composition of Ly5.1+/+ chimeric mice reconstituted with C57BL/6 J (CD45.2+/+) or Il7rCre/+RoraΔ/Δ (CD45.2+/+)28 bone marrow. a, Schematic representation of the experimental design. b-d, Representative flow cytometric contour plots (left panels) and enumeration (right panels) of splenic (b) and tumor-infiltrating (c and d) eosinophils, dendritic cells (DC), neutrophils and macrophages at day 13 after Ret tumor cell inoculation. Immune subsets were defined as eosinophils: live CD45.2+CD64-F4/80-CD3ε-CD19-CD11c+/-MHCII+/-CD11b+Siglec-F+Ly6G- cells; DC: live CD45.2+CD64-F4/80-CD3ε-CD19-CD11c+MHCII+ cells; macrophages: live CD45.2+CD64+F4/80+ cells; neutrophils: live CD45.2+CD64-F4/80-CD3ε-CD19-CD11c+/-MHC II+/-CD11b+Siglec-F-Ly6G+ cells. d, Tumor-infiltrating DC were segregated into CD11b+ DC and CD103+ DC. b-d, Data are pooled from 2 independent experiments (n = 6 mice/genotype/experiment) and show the mean ± s.e.m. Each dot represents one mouse. b-f, Statistical differences were assessed using unpaired Student’s t tests and exact p-values are indicated.
